Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Rhea-AI Summary
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has announced its participation in the 2025 BIO CEO & Investor Conference.
The event will take place on February 10-11, 2025, at the New York Marriott Marquis. Company management will deliver a corporate presentation on Tuesday, February 11, 2025, at 10:15 AM EST in the Royale Room. The presentation will subsequently be made available in the Investors section of the company's website under the Event Calendar tab.
Management will also be available for one-on-one meetings with registered investors and conference attendees. Interested parties are encouraged to schedule meetings through the BIO CEO attendee portal.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PLX gained 4.13%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST
CARMIEL,
Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees. Following the presentation, a copy will be available under the Event Calendar tab in the Investors section of the Company's website.
Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
617 308 4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-the-2025-bio-ceo--investor-conference-302367286.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When is Protalix BioTherapeutics (PLX) presenting at the 2025 BIO CEO Conference?
Where can investors access PLX's 2025 BIO CEO Conference presentation materials?
How can investors schedule one-on-one meetings with PLX management at the BIO CEO Conference?
What is the location of the 2025 BIO CEO Conference where PLX will present?
What dates will the 2025 BIO CEO Conference featuring PLX take place?
